CAR-MAIT Cells Targeting TCR-Vbeta 7.1 for Allogeneic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies are limited in treating T-cell malignancies like T-cell lymphoma due to autologous transfusion limitations, on-target/off-tumor toxicity, and variability in patient T-cell function, and existing methods for expanding MAIT cells are difficult for large-scale production and quality control, making them unsuitable for allogeneic adoptive transfer.
Innovation Solution
Development of novel genetic constructs and methods to stimulate and isolate highly purified MAIT cells, which are then engineered into CAR-MAIT cells capable of targeting CD4 or TCR-Vbeta 7.1 chains, allowing for allogeneic transfer and improved efficacy against T-cell malignancies and solid tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cell therapy is used to treat T-cell malignancies, then the treatment can be performed, but it is limited by autologous transfusion requirements, graft-versus-host disease risk, and on-target/off-tumor toxicity
Solution Approach 1:
The patent segments the T cell population by specifically isolating and expanding MAIT cells (a distinct T cell subset) rather than using conventional CAR-T cells. This segmentation allows targeting of T-cell malignancies while preserving normal T cells that express different markers, thereby reducing on-target/off-tumor toxicity and graft-versus-host disease risk while maintaining treatment effectiveness
Solution Approach 2:
The patent uses novel genetic constructs as intermediaries to engineer CAR-MAIT cells with enhanced specificity. These genetic constructs mediate the integration of chimeric antigen receptor genes into MAIT cells, enabling precise targeting of malignancies while reducing harmful effects through improved selectivity
2Quantity of substance
If existing methods for expanding MAIT cells are used, then MAIT cells can be obtained, but large-scale production and quality control are difficult
Solution Approach 1:
The patent applies preliminary action by pre-isolating and pre-expanding MAIT cells using specific culture conditions and markers before genetic modification. This preliminary preparation establishes a standardized, high-quality cell population that simplifies subsequent large-scale production and quality control processes
Solution Approach 2:
The patent changes key parameters of MAIT cell isolation and expansion, including using specific surface markers (CD161, TCR-Vα7.2), optimized culture conditions, and novel genetic constructs. These parameter changes enable scalable production while maintaining consistent quality and purity of CAR-MAIT cells
3Adaptability or versatility
If conventional CAR-T cells are used, then treatment can be provided, but there is variability in patient T cell function and product standardization is difficult
Solution Approach 1:
The patent uses universal MAIT cells with invariant TCR receptors that recognize conserved microbial antigens presented by MR1. This universality allows for standardized, off-the-shelf products with consistent function across patients, eliminating variability while maintaining therapeutic effectiveness through the conserved MAIT cell pathway
Data Source
AI summary
The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-T-cell receptor (TCR) V-beta CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.